TY  - JOUR
AU  - Perez, Marco
AU  - Peinado-Serrano, Javier
AU  - Garcia-Heredia, Jose Manuel
AU  - Felipe-Abrio, Irene
AU  - Tous, Cristina
AU  - Ferrer, Irene
AU  - Martin-Broto, Javier
AU  - Saez, Carmen
AU  - Carnero, Amancio
PY  - 2016
DO  - 10.18632/oncotarget.11475
UR  - http://hdl.handle.net/10668/10392
T2  - Oncotarget
AB  - Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are...
LA  - en
KW  - MAP17
KW  - biomarker
KW  - bortezomib
KW  - sarcomas
KW  - PDX
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Animals
KW  - Antineoplastic Agents
KW  - Area Under Curve
KW  - Biomarkers, Tumor
KW  - Bortezomib
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Membrane Proteins
KW  - Mice
KW  - Middle Aged
KW  - Prognosis
KW  - ROC Curve
KW  - Sarcoma
KW  - Sensitivity and Specificity
KW  - Xenograft Model Antitumor Assays
KW  - Young Adult
TI  - Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).
TY  - research article
VL  - 7
ER  -